trial

Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia

NCTId NCT00838032
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 70 (estimated)
Sponsored by Sichuan University
Primary completion 2010-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
70 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2008-08
Primary completion
2010-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
QuetiapineHaloperidol

Sponsors

Sichuan UniversityLead Sponsor

Investigators

1
Tao Chun Liu, DirectorStudy Director

Sites

1 total
Chengdu, China

Facts & assertions

4 sourced
Enrollment
70
Phase
PHASE4
Primary Completion Date
2010-05
Status
UNKNOWN
relationships
The graph out of here
drug
Quetiapine
drug
Haloperidol
drug
lead_sponsor
Sichuan University
company
indication
Acute Schizophrenia
indication
investigator
Tao Chun Liu, Director
person